Comparison of the outcomes of patients with primary central nervous system lymphoma between the neurosurgery and hematology/oncology departments based on the relative dose intensity of methotrexate

Hosoi,Hiroki; Hosoi,Hiroki; Okamura,Tadashi; Okamura,Tadashi; Fukai,Junya; Fukai,Junya; Hori,Yoshikazu; Hori,Yoshikazu; Murata,Shogo; Murata,Shogo; Mushino,Toshiki; Mushino,Toshiki; Nakao,Naoyuki; Nakao,Naoyuki; Sonoki,Takashi; Sonoki,Takashi

doi:10.3892/ol.2023.14056

Comparison of the outcomes of patients with primary central nervous system lymphoma between the neurosurgery and hematology/oncology departments based on the relative dose intensity of methotrexate

Authors:
- Hiroki Hosoi
- Tadashi Okamura
- Junya Fukai
- Yoshikazu Hori
- Shogo Murata
- Toshiki Mushino
- Naoyuki Nakao
- Takashi Sonoki
View Affiliations

Affiliations: Department of Hematology/Oncology, Wakayama Medical University, Wakayama 641‑8509, Japan, Department of Neurological Surgery, Wakayama Medical University, Wakayama 641‑8509, Japan
Published online on: September 19, 2023 https://doi.org/10.3892/ol.2023.14056
Article Number: 469

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Primary central nervous system lymphoma (PCNSL) is an extranodal type of lymphoma, which is treated with methotrexate (MTX)‑based induction therapy. Although PCNSL is a hematological malignancy, patients with PCNSL may be treated at neurosurgery or hematology/oncology departments; however, the outcomes of PCNSL treatment have not been compared between these two departments. The present study compared the outcomes of 26 patients with newly diagnosed PCNSL that were treated at the Department of Neurological Surgery or Department of Hematology/Oncology (Wakayama Medical University Hospital, Wakayama, Japan) between January 2011 and December 2021. The relative dose intensity (RDI) and relative treatment intensity of MTX were assessed as indicators of the intensity of chemotherapy. The median RDI of MTX was 67 and 93% in the neurosurgery and hematology/oncology groups, respectively (P<0.001). The proportion of patients that achieved a complete response after high‑dose MTX‑based therapy was significantly higher in the hematology/oncology group than in the neurosurgery group (P=0.038). The estimated 2‑year overall survival was 72 and 100% in the neurosurgery and hematology/oncology groups, respectively (P=0.046). As with the difference in the outcomes observed between pediatrics and hematology departments for adolescents with acute lymphoblastic leukemia, the outcomes of patients with PCNSL may differ between neurosurgery and hematology/oncology departments.

View Figures

View References

1	Schaff LR and Grommes C: Primary central nervous system lymphoma. Blood. 140:971–979. 2022. View Article : Google Scholar : PubMed/NCBI
2	Stock W: Adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2010:21–29. 2010. View Article : Google Scholar : PubMed/NCBI
3	Hirakawa T, Yamaguchi H, Yokose N, Gomi S, Inokuchi K and Dan K: Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma. Ann Hematol. 89:897–904. 2010. View Article : Google Scholar : PubMed/NCBI
4	Bataillard EJ, Cheah CY, Maurer MJ, Khurana A, Eyre TA and El-Galaly TC: Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: A systematic review. Blood Adv. 5:2426–2437. 2021. View Article : Google Scholar : PubMed/NCBI
5	Farhi J, Laribi K, Orvain C, Hamel JF, Mercier M, Galy AS, Clavert A, Rousselet MC, Tanguy-Schmidt A, Hunault-Berger M and Moles-Moreau MP: Impact of front line relative dose intensity for methotrexate and comorbidities in immunocompetent elderly patients with primary central nervous system lymphoma. Ann Hematol. 97:2391–2401. 2018. View Article : Google Scholar : PubMed/NCBI
6	Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, et al: Prognostic scoring system for primary CNS lymphomas: The international Extranodal lymphoma study group experience. J Clin Oncol. 21:266–272. 2003. View Article : Google Scholar : PubMed/NCBI
7	Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta M and DeAngelis LM: Primary central nervous system lymphoma: The Memorial Sloan-Kettering cancer center prognostic model. J Clin Oncol. 24:5711–5715. 2006. View Article : Google Scholar : PubMed/NCBI
8	Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, Grimm S, Lai RK, Reiner AS, Panageas K, et al: Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: Final results and long-term outcome. J Clin Oncol. 31:3971–3979. 2013. View Article : Google Scholar : PubMed/NCBI
9	Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis LM, et al: Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 23:5034–5043. 2005. View Article : Google Scholar : PubMed/NCBI
10	Hiroi T, Hosoi H, Kuriyama K, Murata S, Morimoto M, Mushino T, Nishikawa A, Tamura S and Sonoki T: An evaluation based on relative treatment intensity in older patients treated with reduced-dose R-THP-COP therapy for diffuse large B-cell lymphoma: A multicenter retrospective cohort study. J Geriatr Oncol. 14:1013962023. View Article : Google Scholar : PubMed/NCBI
11	Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
12	Kondo E, Ikeda T, Goto H, Nishikori M, Maeda N, Matsumoto K, Kitagawa H, Noda N, Sugimoto S and Hara J: Pharmacokinetics of thiotepa in high-dose regimens for autologous hematopoietic stem cell transplant in Japanese patients with pediatric tumors or adult lymphoma. Cancer Chemother Pharmacol. 84:849–860. 2019. View Article : Google Scholar : PubMed/NCBI
13	Okamura T, Hosoi H, Matsufusa T, Akagi Y, Iwamoto R, Kosako H, Murata S, Mushino T, Murata SI and Sonoki T: Tirabrutinib maintenance therapy for a patient with high-dose methotrexate-ineligible primary central nervous system lymphoma. Ann Hematol. 101:1379–1381. 2022. View Article : Google Scholar : PubMed/NCBI
14	Boissel N, Auclerc MF, Lheritier V, Perel Y, Thomas X, Leblanc T, Rousselot P, Cayuela JM, Gabert J, Fegueux N, et al: Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 21:774–780. 2003. View Article : Google Scholar : PubMed/NCBI
15	Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P, Larson RA and Nachman J; Children's Cancer Group, : Cancer and Leukemia Group B studies: What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of children's cancer group and cancer and leukemia group B studies. Blood. 112:1646–1654. 2008. View Article : Google Scholar : PubMed/NCBI
16	Schiffer CA: Differences in outcome in adolescents with acute lymphoblastic leukemia: A consequence of better regimens? Better doctors? Both? J Clin Oncol. 21:760–761. 2003. View Article : Google Scholar : PubMed/NCBI
17	Lepage E, Gisselbrecht C, Haioun C, Sebban C, Tilly H, Bosly A, Morel P, Herbrecht R, Reyes F and Coiffier B: Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol. The GELA (Groupe d'Etude des Lymphomes de l'Adulte). Ann Oncol. 4:651–656. 1993. View Article : Google Scholar : PubMed/NCBI
18	Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, et al: Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: Results of the first randomisation of the international Extranodal lymphoma study group-32 (IELSG32) phase 2 trial. Lancet Haematol. 3:e217–227. 2016. View Article : Google Scholar : PubMed/NCBI
19	Kasenda B, Ferreri AJ, Marturano E, Forst D, Bromberg J, Ghesquieres H, Ferlay C, Blay JY, Hoang-Xuan K, Pulczynski EJ, et al: First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)-a systematic review and individual patient data meta-analysis. Ann Oncol. 26:1305–1313. 2015. View Article : Google Scholar : PubMed/NCBI
20	Hoang-Xuan K, Bessell E, Bromberg J, Hottinger AF, Preusser M, Rudà R, Schlegel U, Siegal T, Soussain C, Abacioglu U, et al: Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: Guidelines from the European association for neuro-oncology. Lancet Oncol. 16:e322–332. 2015. View Article : Google Scholar : PubMed/NCBI
21	Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, Binder M, Fabbri A, Torri V, Minacapelli E, et al: Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: Results of the second randomisation of the international Extranodal lymphoma study group-32 phase 2 trial. Lancet Haematol. 4:e510–e523. 2017. View Article : Google Scholar : PubMed/NCBI
22	Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, Moluçon-Chabrot C, Soubeyran P, Gressin R, Choquet S, et al: Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: Results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J Clin Oncol. 37:823–833. 2019. View Article : Google Scholar : PubMed/NCBI
23	Sasaki N, Kobayashi K, Saito K, Shimizu S, Suzuki K, Lee J, Yamagishi Y, Shibahara J, Takayama N, Shiokawa Y and Nagane M: Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy. Jpn J Clin Oncol. 50:999–1008. 2020. View Article : Google Scholar : PubMed/NCBI
24	Patel AM, Ali O, Kainthla R, Rizvi SM, Awan FT, Patel T, Pan E, Maher E, Desai NB, Timmerman R, et al: Primary central nervous system lymphoma: A real-world comparison of therapy access and outcomes by hospital setting. Neurooncol Pract. 9:183–192. 2022.PubMed/NCBI
25	Calimeri T, Steffanoni S, Gagliardi F, Chiara A and Ferreri AJM: How we treat primary central nervous system lymphoma. ESMO Open. 6:1002132021. View Article : Google Scholar : PubMed/NCBI